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Background/aim: This study aimed to investigate the expression of chemokine receptor 4 (CXCR-4) and cyclooxygenase-2 (COX-2) in
the epithelium and stroma of pterygium tissue in comparison with healthy conjunctiva.
Materials and methods: The expression of CXCR4 and COX-2 was investigated by immunohistochemistry in the epithelium and
stroma of the pterygium tissue of 29 eyes and compared with healthy conjunctival tissues. The correlation between CXCR4 and COX-2
expression as well as the correlation of these markers with the area of pterygium were evaluated statistically.
Results: COX-2 staining scores were 1.75 ± 0.63 in the epithelium and 1.20 ± 0.62 in the stroma of the pterygium tissue. Mean CXCR-4
staining in the epithelium was 0.069 ± 0.37, whereas it was 5.0 ± 2.84 cells in the stroma. There was almost no staining of COX-2 and
CXCR4 in the control samples. There was a strong positive correlation between the expression of CXCR-4 and COX-2 in the stroma of
the pterygium.
Conclusion: CXCR-4 and COX-2 may play important roles in the pathogenesis of pterygium.
Key words: CXCR-4, cyclooxygenase-2, pterygium

1. Introduction
Pterygium is a fibrovascular tissue growing on the ocular
surface. This disease demonstrates both hyperplastic
and degenerative properties, as well as some tumorlike features. Irritation of the ocular surface by excessive
ultraviolet (UV) light and repeated microtrauma seem
to be the leading contributing factors to pterygium
development in susceptible individuals (1). UV light
exposure also plays an important role in skin tumors
(2). Tumor-like characteristics of pterygium, such as a
propensity to invade normal tissue, high recurrence rates
following resection, epithelial proliferation, goblet cell
hyperplasia, angiogenesis, inflammation, elastosis, stromal
plaques, Bowman’s membrane dissolution, inactivation
of the p53 tumor suppressor gene, and coexistence with
ocular surface neoplasms, have been reported in previous
studies (3–5).
Chemokines are polypeptides of 8–14 kDa in size that
have the properties of signaling molecules. CXCR-4 is a
member of the chemokine receptor family. The interaction
between CXCR-4 and stromal cell-derived factor (SDF1α), its ligand, is known to play an important role in tumor
* Correspondence: drgonenbaser@gmail.com

genesis, metastasis, and angiogenesis (6,7). This biological
role is demonstrated in different types of tumors including
malignant melanoma, glioblastoma, and lung, breast,
pancreatic, and cholangiocellular carcinomas (8–12).
UV-induced abnormal prostaglandin synthesis is
reported to be an important factor in the development of
cancer. Cyclooxygenase (COX) is an enzyme that catalyzes
the conversion of free arachidonic acid to prostaglandins.
It has two isoforms, known as COX-1 and COX-2. COX1 is found mostly in normal tissue and is required for
physiological functions (13). COX-2 is expressed only
under special conditions like hypoxia or by the influence
of growth factors or cytokines. COX-2 is also known to be
expressed in many neoplastic processes, like stimulation
of cell division, angiogenesis, and inhibition of apoptosis
(14,15).
Expression of COX-2 was reported in pterygium in
previous studies (16) and there is only one article regarding
CXCR-4 expression in pterygium (17). Although the
relation of COX-2 and CXCR-4 was investigated in skin
tumors (18), to our knowledge this relationship was not
studied in pterygium
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We planned this study to investigate the expression
of CXCR-4 and COX-2 in the epithelium and stroma of
primary pterygium tissue to determine their importance
in the pathogenesis of pterygium. We also evaluated the
correlation between the area of pterygium and CXCR-4
and COX-2.
2. Materials and methods
This prospective study was approved by the ethics
committee of Şifa University. All procedures were
performed according to the tenets of the Declaration of
Helsinki, and informed consent was obtained from all
patients. The authors declare no conflicts of interest.
Prior to the operation, the pterygium area was
measured as mm2 with a slit lamp. Samples were collected
from 29 eyes of 29 patients with primary pterygium who
were operated on during the period of March 2013 to
February 2014. Patients with a history of ocular trauma,
surgery, inflammatory or malignant ocular surface
diseases, chemical burns, use of systemic or topical
steroids or any eye drops in the last 6 months before
surgery, and recurrent pterygia were excluded from the
study. The specimens were harvested intraoperatively from
each eye during standard pterygium removal surgery. All
patients had pterygium excision combined with limbal
conjunctival autograft by the same surgeon (GB) using a
standard technique (15). The limbal conjunctival autograft
was taken from the upper bulbar conjunctiva. A piece was
excised from the nasal edge of the conjunctival autograft
from 11 patients to make the control group samples.
2.1. Histological evaluation of CXCR-4 and COX-2
Tissues were fixed in 10% formaldehyde solution and
after the tissue processing procedure were embedded in
paraffin blocks. Three sections of 4 µm in thickness were
taken from each paraffin block. One section was stained
with hematoxylin and eosin and the other 2 positively
charged slides were stained by DAKO Autostainer 48
Link (Dako, Denmark) with COX-2 (DAKO, Clone CX294, 1/100 dilution) and CXCR-4 (Abcam, Clone ab 2074,
1/50 dilution) antibodies. The slides were then evaluated
under a light microscope by two pathologists. Cytoplasmic
staining was accepted as positive for both antibodies.
Epithelial
COX-2
expression
was
scored
semiquantitatively according to the percentage of positivestaining cells: 0, negative staining; +, from 1% to 10%;
++, from 11% to 50%; and +++, more than 50% positive
cells. COX-2 expression in the stroma was scored for the
average number of cells expressing COX-2 with the most
extensive staining in the high-power field: 0, no positive
cells; +, 1 to 5 positive cells; ++, 6 to 10 positive cells; and
+++, more than 10 positive cells, according to the method
of Park et al. (19). Positively stained cells were counted in
the most intensely stained high-power field for CXCR-4
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evaluation for the stroma and the epithelium. There were
very few positively stained cells in both compartments, not
allowing semiquantitative scoring.
2.2. Statistical analysis
SPSS 11.6 (SPSS Inc., Chicago, IL, USA) was used. The
differences of sex and the level of COX-2 between the
groups were analyzed by chi-square test. The age and
the level of CXCR-4 of the two groups were compared
with independent samples t-test. Paired samples t-tests
were used to compare the epithelium and stroma
regarding CXCR-4 expression. The chi-square test was
used to compare the epithelium and stroma regarding
the expression of COX-2. The correlation of the area of
pterygium with CXCR-4 and COX-2 expression and the
correlation between CXCR-4 and COX-2 expressions were
evaluated by Pearson correlation analysis.
3. Results
The patients consisted of 13 men (44.8%) and 16 women
(55.2%). Mean age of the patients was 51.9 ± 12.9 (range:
26–79) years. Six of the control patients were males and
five were females. Mean age in the control group was 55.5
± 16.5 (range: 26 to 79) years.
The COX-2 staining of the epithelium ranged from
1 (+) to 3 (+++) (mean: 1.75 ± 0.63). The intensity was
moderate (++) to strong (+++) in 67% of the cases. The
COX-2 staining of the stroma ranged from 1 (+) to 2 (++)
(mean: 1.20 ± 0.62). The staining was absent in 10% of the
cases, whereas weak to moderate staining was observed in
90% of the cases. In the control group, the COX-2 staining
of the epithelium was 0 (+) to 1 (+) (mean: 0.18 ± 0.40) and
it was 0 ± 0.0 (+) in the stromal cells.
The COX-2 expression scores were higher in the
epithelium and stroma of the primary pterygium group
when compared with the control group (P < 0.001). The
COX-2 cell staining intensity was higher in the epithelial
cells than the stromal cells in the pterygium tissue (P <
0.001).
The CXCR-4 staining in the epithelium ranged from
0 to 2 cells (mean: 0.069 ± 0.37) in only one patient. The
CXCR-4 staining in the stroma ranged from 1 to 10 cells
(mean: 5.0 ± 2.84). The staining of CXCR-4 was 0.00 ± 0 in
the epithelium and 0 to 1 cells (mean: 0.18 ± 0.40) in the
stromal cells of the control group. There was no statistically
significant difference between the primary pterygium
and control groups regarding CXCR-4 expression in the
epithelium (P = 0.545). The CXCR-4 expression in the
stroma of the primary pterygium group was statistically
higher than that of the control group (P < 0.001). The
CXCR-4 cell staining intensity in the stromal cells was
higher than in the epithelium (P < 0.001) in the pterygium
tissue, and it was predominantly located in perivascular
areas and fibroblastic cells (Table; Figures 1a–1l).
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Table. Age, sex, and CXCR-4 and COX-2 levels in pterygium and control groups. 		
Pterygium group

Control group

51.9 ± 12.9

55.5 ± 16.4

Sex

13 men/16 women

6 men/5 women

-

Area of the pterygium (mm2)

9.2 ± 6.3

-

-

CXCR-4 level in the epithelium

0.07 ± 0.37

0.0 ± 0.0

P-value: 0.545

COX-2 in the epithelium

1.7 ± 0.6

0.2 ± 0.4

P-value: 0.001*

CXCR-4 level in the stroma

5.0 ± 2.8

0.2 ± 0.4

P-value: 0.001*

COX-2 level in the stroma

1.2 ± 0 .6

0.0 ± 0.0

P-value: 0.001*

Age

The mean area of the pterygium was 9.17 ± 6.27 mm2
(4–24 mm2). The control tissues were cut into 1 × 2 mm
pieces. The correlation between the area of pterygium
and the CXCR-4 of the epithelium was not significant
(R = 0.159, P = 0.411). There was a moderate positive
correlation between the area of pterygium and CXCR4 expression in the stroma (R = 0.725, P < 0.001). The
relation of the area of the pterygium and the expression
of COX-2 in the epithelium was not significant (R = 0.288,
P = 0.129). There was a strong correlation between the
area of the pterygium and the COX-2 in the stroma (R =
0.560, P = 0.002). There was no correlation between the
levels of CXCR-4 and COX-2 in the epithelium (R = 0.073,
P = 0.707). There was a moderate correlation between the
expressions of CXCR-4 and COX-2 in the stroma (R =
0.649, P < 0.001).
4. Discussion
Although the exact pathogenesis of pterygium is still
unclear, chronic inflammation, angiogenesis, and
uncontrolled proliferation seem to be the key mechanisms
in progression (1,5,20). Several inflammatory and
angiogenic factors, such as VEGF, MMP, and TGF, were
suggested to be related to its pathogenesis (21–23). In
the present study, we investigated the cell expressions of
COX-2 and CXCR-4 in pterygium tissue. The interaction
between COX-2 and CXCR-4 has been demonstrated in
various types of UV-exposed malignant skin tumors and
cancers (19).
COX-2 expression in human pterygium has been
previously studied. Chiang et al. found that more than 80%
of pterygium tissue studied showed positive expression of
COX-2 in the epithelium; however, they found no COX2 expression in the stroma (24). Subsequent studies by
Adigüzel et al. (25), Karahan et al. (26), and Maxia et
al. (27) reported COX-2 expression in the epithelium of
primary pterygia in 60%, 84.2%, and 67.7% of the cases,
respectively. Karahan and Maxia also reported COX-2

P-value: 0.463

expression in the stroma. Park et al. (17) reported more
intense epithelial staining of COX-2 expression and they
found that stromal COX-2 expression was increased with
vascularity. In our study, COX-2 expression was observed
in both epithelial and stromal cells, as in the studies of
Park et al., Karahan et al., and Maxia et al. (19,26,27).
The COX-2-positive cell intensity in the epithelial cells
was higher than that of the stromal cells in the pterygium
tissue. This may be related to the early and/or predominant
superficial conjunctiva epithelial inflammatory response,
which is prone to UV injury. As mentioned before, COX-2
expression was reported in UV-exposed skin tumors, and
considering the tumor-like characteristics of pterygium
tissue, the development of pterygium might have a similar
pathway to that of skin tumors (18,28).
To the best of our knowledge, CXCR-4 expression
in pterygium was investigated only in one study. Kim
et al. (17) demonstrated a positive correlation between
the severity of pterygium and SDF-1 expression. They
postulated the possible contribution of SDF-1 and CXCR4 interaction to myofibroblastic transformation, which
can be possibly restored through the downregulation of
the SDF-1/CXCR-4 axis. Myofibroblasts found at the site
of tissue injury are considered to play a pivotal role in
the healing process. By secreting ECM proteins and the
contractile protein alpha-smooth muscle actin (α-SMA),
myofibroblasts promote tissue repair (29). Additionally,
these cells are also reported to exist in the fibrovascular
tissue of pterygia (30). Indeed, various studies reported that
the development of pterygium might result from reactive
wound formation triggered by oxidative stress due to UV
light exposure, ocular irritation, and/or inflammation on
the ocular surface (17,31,32). In our series the expression
of CXCR-4 was confined to the stroma and there was a
significant correlation between the body surface and
CXCR-4 and COX-2 expression in the stromal part of
the pterygium, which is in close contact with the surface
epithelium exposed to UV light. This might activate the

1063

BAŞER et al. / Turk J Med Sci

Figure 1. COX-2 and CXCR-4 expressions in pterygium stroma and epithelium. COX-2 expression
in different cases: a, b, c, d- epithelium at -/+/++/+++, respectively; e, f, g, h- stroma at -/+/++/+++,
respectively (IHC, COX-2, original magnification 40×). CXCR-4 expression: i- epithelium (-); jstroma (-); k- positive in the epithelium; l- positive in the stroma (positivity in rare cells not allowing
semiquantitative scoring and evaluated by cell counting) (IHC, CXCR-4, original magnification 40×).
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transformation of fibroblasts to myofibroblasts and may
promote the development of the stroma of the pterygium.
It was reported in a recent study that activities of COX-2/
PGE2-EP3/EP4 signaling modulate tumor biology and it was
shown that the CXCL-12/CXCR-4 axis could play a crucial
role in tumor stromal formation and angiogenesis under the
control of prostaglandins. It was postulated that PGE2-EP3/
EP4 signaling in tumor stroma may promote tumor stromal
formation and tumor growth mainly through the host CXCL12/CXCR-4 axis by recruiting stromal fibroblasts (33). On the
other hand, Obermajer et al. (34) demonstrated that COX-2
inhibition also blocked CXCL-12/CXCR-4 production in the
ovarian cancer environment and its ability to attract MDSCs.
These mechanisms may raise the possibility of new therapeutic
targets to treat pterygia. Kim et al. (17) reported that cultured
pterygial fibroblasts treated with CXCR-4 antagonist AMD3100 demonstrated lower cellular expression of α-SMA,
which promotes tissue repair.
Our study has its limitations. The small sample size
is the first limitation. Another important point was the

evaluation of the apex and the body of the pterygium
separately. The apex and the body of the pterygium
may have different morphological and/or phenotypical
characteristics and evaluation of the expression COX2 and CXCR-4 separately in these sites may provide
additional information.
To the best of our knowledge, there is no previous
study investigating both COX-2 and CXCR-4 in the same
pterygium series. The novel finding of this study is the
moderate positive correlation between the expression of
CXCR-4 and COX-2 in the stroma. The pterygium area is
also moderately correlated with the stromal expressions
of CXCR-4 and COX-2. These findings highlight the
importance of the stroma and CXCR-4 and COX-2 in
pterygium, which may lead to further therapeutic studies
with inhibitors of CXCR-4 and COX-2. The “seed and soil”
hypothesis proposed by Sir James Paget more than 100
years ago in favor of the importance of the stroma in tumor
progression may be also important in the understanding
and prevention of the growth of pterygium (35).
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